Pfizer To Acquire Global Blood Therapeutics For $5.4 Billion To Enhance Presence In Rare Hematology
Acquiring Company
Pfizer
Acquired Company
Global Blood Therapeutics
New YorkBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmapharmaceuticalsBiotechnologyHealth CareTherapeuticsDescription
Pfizer Inc. (NYSE: PFE) and Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the companies have entered into a definitive agreement under which Pfizer will acquire GBT, a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities, starting with sickle cell disease (SCD). The acquisition complements and further enhances Pfizer’s more than 30-year heritage in rare hematology and reinforces the company’s commitment to SCD by bringing expertise and a leading portfolio and pipeline with the potential to address the full spectrum of critical needs in this underserved community. Pfizer intends to continue to build on the companies’ shared commitment to and engagement with the SCD community.
Quick answer
Pfizer is acquiring Global Blood Therapeutics for $5.4 billion, announced August 8, 2022. Pfizer is based in New York, New York, United States.
- How much did Pfizer pay for Global Blood Therapeutics?
- The reported deal value is $5.4 billion.
- Where are Pfizer and Global Blood Therapeutics based?
- Pfizer is based in New York, New York, United States.
- Who are the decision-makers at Pfizer?
- Fundz holds 2 contacts at Pfizer. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who to call at Pfizer, and when
When Pfizer changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Pfizer raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Pfizer, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Pfizer. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Pfizer makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Global Blood Therapeutics?
Global Blood Therapeutics was acquired by Pfizer, based in New York. The deal was reported on August 8, 2022. Pfizer is publicly traded (PFE) and operates in Biotechnology.
When did Pfizer acquire Global Blood Therapeutics?
Pfizer's acquisition of Global Blood Therapeutics was reported on August 8, 2022. Pfizer Inc. (NYSE: PFE) and Global Blood Therapeutics, Inc. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Global Blood Therapeutics do?
Global Blood Therapeutics, Inc. (GBT) is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities, starting with sickle cell disease (SCD). It is privately held, operating in Biotechnology.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.